Background: Surgery for acute type A aortic dissection (ATAAD) is often complicated by excessive bleeding. Recombinant factor VIIa (rFVIIa) effectively treats refractory bleeding associated with ATAAD surgery; however, adverse effects of rFVIIa in these patients have not been fully assessed. Here we evaluated rFVIIa treatment in ATAAD surgery using the Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) database.
Forest plot illustrating the associations between rFVIIa treatment and primary endpoints.
Central Message
The results of this study showed that patients undergoing rFVIIa treatment in association to ATAAD surgery did not display significantly greater rates of mortality, renal replacement therapy or stroke.
Perspective
In previous studies on standard and complex cardiac surgery, use of recombinant factor VIIa (rFVIIa) has been associated with increased rates of mortality and stroke. In this study of a large sample of patients undergoing acute type A aortic dissection surgery, treatment with rFVIIa for major bleeding was not associated with a significantly increased risk of stroke, the need for renal replacement therapy (RRT), or mortality.
See Editorial Commentary page 1860.
Despite significant surgical advances in recent years, acute type A aortic dissection (ATAAD) still poses a great clinical challenge, with high mortality and morbidity. 1, 2 Bleeding complications related to cardiac surgery adversely affect surgical outcomes. 3, 4 The pathology of aortic dissection is known to cause dysregulation of the coagulation system, augmented by cardiopulmonary bypass (CPB) and deep hypothermia. [5] [6] [7] Consequently, massive intraoperative and postoperative bleeding is a feared complication associated with considerably elevated morbidity and mortality. 8, 9 Since first described in 2001, 10 recombinant factor VIIa (rFVIIa) (Novoseven; Novo Nordisk A/S, Bagsvaerd, Denmark) has gained increasing use for treating refractory bleeding in the off-label setting of cardiothoracic surgery. Previous studies have reported that rFVIIa effectively reduces blood loss and the need for allogeneic blood transfusions in standard cardiac surgery 11, 12 ; however, questions have been raised as to whether the prothrombotic properties of rFVIIa lead to an increased risk of thromboembolic complications when used in patients without hemophilia. 13, 14 Data on the use of rFVIIa in ATAAD surgery are scarce, and previous studies are limited by small sample sizes. 11, 15 The Nordic Consortium for Acute Type A Aortic Dissection (NORCAAD) is a joint database consisting of 1159 patients who underwent surgery for ATAAD at 8 tertiary centers in Denmark, Finland, Iceland, and Sweden between 2005 and 2014. 16 In the present study, we used the NOR-CAAD database to evaluate the effect of rFVIIa on mortality and rates of postoperative stroke and renal replacement therapy (RRT) after ATAAD surgery.
METHODS
This study was approved by the Institutional Review Board of each participating center.
Study Design
This was a multicenter, propensity score-matched study using data collected retrospectively from the NORCAAD database for patients who underwent ATAAD surgery between January 1, 2005, and December 31, 2014, at 8 Nordic centers. A total of 194 clinical variables were collected from 1159 patients, including demographic data, previous medical history, preoperative medications, clinical symptoms on presentation, diagnostic methods, operative variables, complications, bleeding and blood transfusions, laboratory values, and outcome data. 16 Primary endpoints were in-hospital mortality, perioperative stroke, and RRT. Secondary endpoints were reexploration for bleeding and long-term mortality. In-hospital mortality was defined as death occurring during the hospital stay. Stroke was defined as a clinically significant loss of neurologic function caused by an ischemic event with or without confirmation by computed tomography scan. RRT was defined as the postoperative need for continuous venovenous hemofiltration or hemodialysis.
Postoperative bleeding was defined as total chest tube output volume during the first 24 hours after surgery. Postoperative cardiac tamponade was defined as pericardial effusion necessitating pericardial drainage or reexploration. Transfusions were reported as units of packed red blood cells (PRBCs), platelets, or fresh frozen plasma (FFP), administered at any time during the hospital stay.
Surgical Procedures
The decision to operate for ATAAD and the specific techniques used were at the discretion of the responsible surgeons at each center. Standard median sternotomy, CPB, and intermittent cardioplegic arrest were routinely used as described previously. 16 Cannulation sites varied by center, patient, and surgeon. In cases where a cross-clamp was not used, resection and inspection of the aortic arch were performed with the patient under deep (<20 C) or moderate (21 C-32 C) hypothermic circulatory arrest, with or without the use of antegrade cerebral perfusion.
The method of ascending aorta or aortic arch replacement depended on the location of the intimal tear and the extent of dissection. Root replacement was performed when the tear involved the coronary ostia or aortic valve, or in the presence of an aortic root aneurysm. Operations that involved the aortic arch entailed reimplantation of any supra-aortic branch. When required, the competence of the aortic valve was restored as feasible via subcommissural plication, commissural resuspension, or valvuloplasty. Concomitant procedures (eg, coronary artery bypass) were performed when required.
Management of intraoperative and postoperative bleeding varied depending on the center and time. However, rFVIIa was used mainly during surgery or in the intensive care unit when primary pharmacologic treatment to reduce bleeding had failed.
Statistical Analysis
Categorical variables were expressed as number and percentage, and continuous variables are presented as median and interquartile range (IQR). A propensity analysis was performed to adjust for differences between the 2 groups. 17 As a first step, univariate logistic regression analyses with group as outcome were performed for all variables listed in Table 1 . All variables with a P value <.20 were subsequently included in the multivariable logistic regression model, which computed the propensity scores. These variables were bicuspid aortic valve, previous cardiac surgery, history performed using the propensity scores. This resulted in the matching of 120 out of a maximum of 127 possible pairs. The remaining patients did not have the data required for inclusion in the model. The matching was evaluated using standardized mean differences. The paired samples were compared using conditional logistic regression for binary variables. Comparisons of the primary endpoints were presented as odds ratios (ORs) with 95% confidence intervals (CIs), and were illustrated using forest plots. Note that these ORs were given by the conditional logistic regression and were based on the discordant pairs. The McNemar-Bowker test was used for categorical variables with more than two categories. All continuous variables in the matched sample met the conditions for a paired t test, which was subsequently used for analysis. The original unpaired sample was compared using the Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables.
Late survival was calculated using Kaplan-Meier estimates, and the groups were compared using the log-rank test. A stratified version was applied for the paired samples. Statistical analyses were performed using R version 3.2.5. (R Project for Statistical Computing; https://www.rproject.org/), and the MatchIt package in R (https://cran.r-project.org/ web/packages/MatchIt/index.html) was used for propensity matching.
RESULTS

Study Population and Follow-up
A total of 1159 patients were included in the NORCAAD database up to March 2017. Follow-up was performed in January 2015 and was 99.5% complete, with a median follow-up time of 2.3 years (range, 0.25-5.23 years). Data on the use of rFVIIa was available for 761 patients (99.5% complete; median follow-up time of 2.2 years; IQR, 0.59-4.63 years). Of these 761 patients, 171 received treatment with rFVIIa (rFVIIa group).
Unmatched Population
The baseline characteristics and intraoperative data for the unmatched groups are presented in Table 1 . Compared with the control group, the rFVIIa group had a more frequent history of stroke (5.8% vs 2.9%; P ¼ .07) and cerebral malperfusion (12 
Matched Population
The propensity score algorithm successfully matched 120 patients who received rFVIIa with 120 control patients. The baseline characteristics and intraoperative data for the matched groups are presented in Table 2 . After propensity score matching, there were no significant differences between the groups, except in preoperative warfarin treatment (11.7% vs 4.2%; P ¼ .049).
A sensitivity analysis of the primary outcomes was performed adjusting for all variables with a standardized absolute difference exceeding 10%. The variables were adjusted for in the conditional logistic regression of the matched dataset, which resulted in minor effects on the ORs, but with no impact on the conclusions of our main analyses.
To further evaluate the propensity score matching, we performed a multivariable logistic regression adjusting for the same variables as those included in the propensity score matching. Even after this adjustment, we found no significant effect on between-group differences in the primary outcomes.
Transfusions and Reexploration for Bleeding
Patients in the rFVIIa group had greater chest tube output during the first 24 hours than controls (mean, 1500 mL [IQR, 835-2500 mL] vs 990 mL [IQR, 520-1720 mL]); however, a comparative analysis of chest tube output between the matched groups was not possible owing to numerous missing values (Table 3 ). In the unmatched samples, data were available for 444 of 761 patients, demonstrating that patients who received rFVIIa bled significantly more during the first 24 hours (median, 1160 mL [IQR, 670-2215 mL] vs 780 mL [IQR, 520-1230 mL]; P < .001) (Table E2) 
Early Mortality and Postoperative Complications
Comparisons between the rFVIIa and control groups for the primary outcomes showed no significant differences in in-hospital mortality (OR, 0.74; 95% CI, 0.34-1.55; P ¼ .487), postoperative stroke (OR, 1.75; 95% CI, 0.82-3.91; P ¼ .163), or RRT (OR, 1.18; 95% CI, 0.48-2.92; P ¼ .839) (Figure 1 ). The binary results for early mortality and postoperative complications are shown in Table 4 . In-hospital mortality was 12.5% in the rFVIIa group and 16.7% in the control group (P ¼ .486), whereas 30-day mortality in the two groups was 15.8% and 18.3%, respectively (P ¼ .743). The postoperative stroke rate was 25.6% in the rFVIIa group and 17.9% in the control group
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Late Mortality
Kaplan-Meier estimates of survival are shown in Figure 2 . There were no significant between-group differences in survival at 1, 3, and 5 years after surgery: 76.7% versus 76.8%, 74.1% versus 72.9%, and 70.9% versus 70.6%, respectively (P ¼ .248, log-rank test).
DISCUSSION
The results of this multicenter, propensity score-matched, retrospective study demonstrated that rFVIIa treatment did not significantly increase the risk of in-hospital mortality, stroke, or RRT after ATAAD surgery. Excessive bleeding poses a significant threat to patients undergoing ATAAD surgery. Transfusion of platelets and FFP together with prothrombin-complex concentrate, fibrinogen concentrate, and tranexamic acid have been used to prevent bleeding complications with varying degrees of success. rFVIIa was first approved in 1996 for use in patients with hemophilia, 18 but over the last 15 years it has emerged as an off-label treatment of last resort for refractory bleeding after open heart surgery. Previous studies on the use of rFVIIa have described outcomes for a variety of cardiac procedures, 12, 19 whereas reports specifically describing the use of rFVIIa in ATAAD surgery have been limited by small sample sizes and risk of type II errors. 11, 15 In the present study, we did not detect any significant differences in in-hospital mortality between patients who received rFVIIa and control patients (12.5% vs 16.7%; P ¼ .486). Our results are consistent with a randomized study conducted by Gill and colleagues 12 in patients undergoing coronary artery bypass grafting and mitral valve or aortic valve surgery. Two previous studies on isolated ATAAD populations did not report any differences in survival or adverse events between patients treated with rFVIIa and controls, although those studies were limited by the small number of cases (23 and 25 patients, respectively). 11, 15 In contrast, our results are not consistent with those of a previous propensity-matched analysis of patients receiving rFVIIa in association to complex cardiac surgery, where Alfirevic and colleagues 19 reported impaired survival in patients treated with rFVIIa. The authors suggested that renal morbidity, possibly caused by prothrombotic effects in the renal vascular bed associated with the use of rFVIIa, could have contributed to the increased mortality. In the present study, we did not find any difference in the incidence of postoperative RRT between the two groups.
Tissue injury following aortic dissection and CPB increases the expression of tissue factor in circulating blood, which provides a substrate for thromboembolism. This may explain why rFVIIa can cause thromboembolic complications, primarily when used in patients without hemophilia. In a meta-analysis of 6 clinical studies, Ponschab and colleagues 14 reported an increased incidence of stroke in patients receiving rFVIIa, and Gill and colleagues 12 found a trend toward a higher incidence of stroke in patients undergoing standard cardiac surgery. Despite the unfavorable effects of increased bleeding volumes, transfusions, and reexploration for bleeding, in the present study we found no significant differences in the incidence of postoperative stroke between patients receiving rFVIIa and controls.
The pathology of aortic dissection causes consumptive coagulopathy, 5 and surgery is often performed under deep hypothermia. Therefore, the effects of rFVIIa in routine cardiac procedures should not be extrapolated to those in ATAAD surgery, and vice versa. It has previously been shown that bleeding complications in ATAAD surgery increase the incidence of adverse events and in-hospital and long-term mortality. 8, 9 In the present study, the patients treated with rFVIIa had significantly larger volumes of blood loss, underwent reexploration for bleeding more frequently, had greater incidence of postoperative cardiac tamponade, and received more transfusions of PRBCs, platelets, and FFP. These effects could be attributed to the fact that patients were not treated with rFVIIa unless there was significant intraoperative or postoperative bleeding. Thus, patients in the rFVIIa group were inherently at a greater risk of mortality and adverse events (including stroke and RRT) before administration of rFVIIa. Therefore, rather than increasing the risk of mortality, treatment with rFVIIa appeared to reduce the risk of adverse effects caused by excessive bleeding.
The present study has several limitations, including its retrospective design. Although to the best of our knowledge, this study is the largest analysis of rFVIIa treatment in an isolated ATAAD population reported to date. Its multicenter nature inherently introduced various surgical techniques, triggers for rFVIIa administration, and protocols for bleeding management and reexploration. The multicenter design also introduced difficulties in terms of collecting missing data. For example, rFVIIa was administered intraoperatively or in the intensive care unit, but the exact timing of rFVIIa administration was not specified in the database. The NORCAAD database enabled us to analyze a comparatively large patient population; however, the risk of type II errors cannot be overlooked. Propensity score matching is associated with a lower grade of evidence than that achieved with a randomized clinical trial. The use of propensity score matching does not control for unmeasured confounders, and missing data among the confounders might decrease the power of the study. In addition, the patients in our study received rFVIIa due to excessive bleeding, which led to selection bias that could have potentially skewed our findings. Administration of rFVIIa is often a treatment of last resort for refractory bleeding in ATAAD surgery; as such, it might be a surrogate for diligent efforts in achieving hemostasis. Thus, despite the efforts to eliminate confounders, the positive or negative effects of rFVIIa observed in this study cannot be attributed exclusively to the use rFVIIa.
CONCLUSIONS
This multicenter, propensity score-matched, retrospective study used data from the NORCAAD database. Our results show that despite the known adverse effects of bleeding and transfusions, patients receiving rFVIIa treatment in ATAAD surgery did not have greater early or late mortality or a significantly greater incidence of postoperative renal failure. However, this study cannot with certainty exclude an association between rFVIIa use and increased risk of postoperative stroke. Prospective, randomized, and placebo-controlled trials are needed to further define the safety and efficacy of rFVIIa in ATAAD surgery (Video 1).
Conflict of Interest Statement
Authors have nothing to disclose with regard to commercial support. 
